One potential approach to overcome the shortage of human donor organs for transplantation might be xenotransplantation using porcine organs. However, the immune response to such discordant xenografts forms several hurdles that are difficult to overcome. The first is the recipient's innate immunity, which leads to hyperacute rejection (HAR) of the transplanted organ. Naturally occurring xenoreactive antibodies (XNAs) from the recipient's blood bind to antigens on graft endothelial cells (ECs) and promote complement activation, which in turn causes injury and activation of the graft endothelium (1) . Depletion ofXNAs from the recipient's circulation by immunoabsorption (2) , depletion of complement by cobra venom factor, fluid-phase complement inhibition by soluble recombinant complement receptor 1 (3) , and genetic engineering of pigs to (over)express human membrane-associated complement-regulatory molecules (CD46, CD55, CD59) were effective in preventing HAR in pig-to-primate models (4) . However, although HAR can be overcome, xenografts still succumb to acute vascular rejection (A VR), also characterized by deposition ofXNAs and complement activation with subsequent EC activation and dysfunction. In addition, infiltration of xenografts with leukocytes was noticed during A VR (5) . Various strategies are currently being tested to prevent and treat A VR; among others, the elimination of the major xenoantigen Galal,3 Gal on porcine ECs by nuclear transfer technique is the most promising (6) . In hamster-and mouse-to-rat heterotopic heart transplantation models, A VR can be overcome by transient depletion of complement with cobra venom factor in combination with continuous administration of cyclosporine A (7) . Under these conditions, the graft ECs are able to express protective genes like HO-l, A20, and Bcl-2, enabling them to "accommodate," that is, to survive despite the presence of EC-specific antibodies and complement (8, 9) .
In addition to the humoral attack, in vivo and in vitro studies of cellular pig-to-human interactions have identified natural killer (NK) cells as an important component of the innate immune response toward xenografts (10, 11) . NKcells are a lymphocyte subset and are equipped with killer immunoglobulin (lg)-like receptors that deliver an inhibitory signal on binding to self-major histocompatibility complex (MHC) class I molecules. Cells that do not bear self-MHC class I on the surface, for example, xenogeneic cells, are susceptible to NK cell-mediated lysis. Moreover, little is known on the nature of activating ligands present on the surface of porcine target cells, which trigger natural cytotoxicity receptors on human NK cells (12) . Nevertheless, protection of the endothelium from both complement-and NK cell-
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. September 15, 2003 LAUMONn mediated injury seems to be crucial for the prevention and treatment of A VR. Physiologically, ECs are covered with a layer of heparan sulfate proteoglycan (HSPG), which is crucial for the anticoagulant and anti-inflammatory properties of the endothelium. As shown by Platt et aI., HSPG is shed from the cell membrane on activation of ECs, exposing a procoagulant and proinflammatory cell surface (13) . We therefore investigated the potential of the semisynthetic glycosaminoglycan analog dextran sulfate (DXS) to replace HSPG and thereby to protect the endothelium from damage mediated by complement and NK cells. DXS is a sulfated, linear or slightly branched polysaccharide (14) and is known to inhibit the classic pathway of complement activation by potentiation ofCl-inhibitor activity and by inhibition of C3 and C4 (15) . Moreover, DXS blocks the alternative pathway of complement activation by interacting with the poly anion binding site of factor H (16) . Recently, we showed that DXS delays HAR in ex vivo xenoperfused pig lungs (17) . In the present study, we confirmed our hypothesis by demonstrating that DXS binds to porcine cells and prevents complement-and NK cell-mediated lysis in functional in vitro assays. Therefore, DXS may be of use as an EC protective substance in xenotransplantation.
MATERIALS AND METHODS

Reagents
Low molecular weight (MW) DXS (MW 5000) (DXS, sodium salt, order no. D-7037) and heparinase (Heparinase I, H-2519) were purchased from Sigma Chemical Company (St. Louis, MO). Fluoresceinlabeled DXS (DXS-Fluo) was prepared as follows: DXS was converted to dimethyl formamide (Sigma) soluble form (DXS-iPr~HEt+) by flash ion-exchange chromatography on a Dowex50 (H +) column, followed by neutralization with N,N-diisopropylethylamine and lyophilization. The free hydroxyl groups ofDXS were then activated by adding 8 mg of 1,1'-carbonyldiimidazole to a solution of 200 mg DXS-iPr~t+ in 2 mL of dimethyl formamide and stirring the mixture for 2 hr at 45.C. After that time, 18 mg of dry fluorescein cadaverine (Molecular Probes Europe, Leiden, The Netherlands) was added, ~nd the mixture was stirred overnight at room temperature. DXS-Fluo was isolated using a LH-20 Sephadex column and acetonitrile-water (1:1) as eluent. After concentration of the fractions containing DXS-Fluo, 50 mg of sodium bicarbonate in 5 mL water was added, and the mixture was lyophilized. Column chromatography (acetonitrile-water, 1:1) of the residue on LH-20 Sephadex gave 105 mg of DXS-Fluo. A substitution rate of 1 mol-% was determined by absorption measurement at 492 nm, meaning that 1% of the DXS molecules were labeled. DXS-Fluo was tested for complement-inhibitory activity in standard hemolytic assays for the classic, alternative, and lectin pathways. The complement inhibitory activity of DXS-Fluo was slightly lower «10%) compared with unlabeled DXS with identical shapes of the inhibition curves.
Buffers and Serum
The following buffers were used: veronal-buffered saline (pH 7.4: 1.8 mM Na-5,5-diethylbarbital, 0.2 mM 5,5-diethylbarbituric acid, 145 mM NaCl), GVB (veronal-buffered saline containing 0.1% gelatin), DGVB (GVB diluted with an equal volume of 6% [w/v) dextrose solution), DGVB2+ (DGVB containing 0.15 mM Ca2+ and 0.5 mM Mg2+), DGVB-MgEGTA (DGVB2+ containing 15 mM Mg2+ and 30 mM EGTA), phosphate-buffered saline (PBS) (0.1 M PBS, pH 7.4), and fluorescence-activated cell sorter (F ACS) buffer (PBS containing 1% bovine serum albumin and 0.02% NaNa). Normal human serum (NHS) was obtained by centrifugation of blood collected from healthy adult volunteers and stored in aliquots at -70.C until use.
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Cell Isolation and Culture
Pig aortic ECs (PAECs) were mechanically isolated from pig aortas and cultured on fibronectin-coated tissue culture plates (Becton Dickinson, Franklin Lakes, NJ). PAECs were grown until confluence in Dulbecco's Modified Eagle's Medium, supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 IJ.gtmL streptomycin (lnvitrogen Corporation, Carlsbad, CA). PAECs were used between passages two and four in all experiments. The pig kidney cell line PK15 (American Type Cultu,re Collection, Manassas, VA) and the SV40-immortalized porcine aorta-derived EC line PED (18) was cultured under the same conditions as PAECs. The humim MHC class I-deficient erythroleukemia cell line K562 and the NK cell line NK92 (19) were both obtained from American Type Culture Collection and maintained in Roswell Park Memorial Institute, 10% fetal calf serum, or MyeloCult H5100 medium (StemCeli Technologies, Vancouver, Canada) containing 500 U/mL of human interleukin-2 (Chiron, Emeryville, CA), respectively. All cell lines were regularly tested for mycoplasma contamination by polymerase chain reaction (Mycoplasma Plus Polymerase Chain Reaction Primer Set, Stratagene, Amsterdam, The Netherlands).
Hemolytic Assays (AP50, CH50, LP50)
Assays for alternative (AP50), classic (CH50), and lectin (LP50) complement pathway activities were modified versions of the tests described earlier <20-22). In brief, 0.1 mL of rabbit erythrocytes (for the AP50 test, loa cells/mL in DGVB-MgEGTA) or antibody-sensitized sheep erythrocytes (for the CHSO test, loa celis/mL in DGVB2+, coated with rabbit anti-sheep red cell stroma antiserum from Sigma) were incubated willi 0.1 mL of serum diluted in the appropriate buffer and incubated for 60 min at 37.C in a shaking water bath. For llie LP50 test, 0.1 mL of diluted serum was incubated in the same way willi 0.1 mL ofa mixture of10S celis/mL chicken E, 0.3X107 cells/mL Saccharomyces cerevisiae (baker's yeast), and 1.5% mannose-binding lectin-deficient serum (Statens Serum Institut, Copenhagen, Denmark). After adding 1.5 mL ice-cold PBS and centrifugation for 7 min at 1750g, hemolysis was determined in the supernatant by measuring the absorbance of released hemoglobin at 412 nm. For llie 100% hemolysis control, 1.5 mL of water was added in place ofPBS. Sheep erythrocytes were purchased from Biomerieux, Marcy l'Etoile, France. Rabbit erythrocytes were obtained from healthy Burgundy rabbits and stored in Alsever solution (Sigma) until use. The rabbits were in-house bred and kept at the animal experimentation facilities in the University Hospital of Bern. The chickens were from the farm of Hans Thiiler, Scheunen, Switzerland. All animals received humane care according to national and international guidelines. was measured using a FACSCalibur (Becton Dickinson). Data were analyzed using the FlowJo software (Tree Star, San Carlos, CA).
Binding of DXS-Fluo to Endothelial Cells
To experimentally damage or activate PAECs (release of HSPG), the cells were trypsinized and then preincubated with 1:4 diluted NHS for 30 min at 37°C (13) . As a control for HSPG release, PAECs were also treated for 1.5 hr at 37"C with 1 U/mL ofheparinase. After incubation with various concentration of DXS-Fluo for 30 min at 37°C, the cells were washed three times, and the fluorescence was measured by FACS. In parallel, the presence of HSPG on the cells was determined with biotinylated mouse anti-human heparan sulfate antibody (Seikagaku, Tokyo, Japan), followed by streptavidin R-phycoerythrin conjugate (Molecular Probes).
Natural Killer Cytotoxicity Assay
The cytotoxic activity of human NK92 cells against PED was tested in standard 51Cr-release assays as described previously (23) . Briefly, unstimulated or tumor necrosis factor (TNF)-a stimulated (human TNF -a, Sigma, 1,000 U/mL for 12 hr at 37") PED target cells were trypsinized and preincubated with 25 mg/mL DXS at 37"C for 30 min and then washed in Hank's buffer without calcium and magnesium (Kantonsapotheke Zurich, Switzerland). Thereafter, target cells were added to triplicate samples of serial twofold dilutions of NK92 cells in round-bottom 96-well plates at effector to target (E:T) ratios ranging from 40:1 to 5:1. After incubation for 4 hr, the release of radioactive 51Cr from labeled PED cells was analyzed on a gamma counter, and the percentage of specific lysis was calculated. All NK cells, used as effectors, efficiently lysed K562 cells, which were used as positive control targets. To calculate the mean percentage of inhibition from four independent experiments, NK92-mediated lysis of PED target cells with and without prior DXS treatment was compared at all four different E:T ratios. P values were determined by the Student paired t test. 
DXS Inhibits All Three Pathways of Complement Activation
Hemolytic assays for the classic (CH50), alternative (AP50), and lectin (LP50) complement pathways were performed to evaluate the efficacy and specificity of complement inhibition by DXS. All complement activation pathways were dose-dependently inhibited by DXS. The concentrations at which 50% inhibition of the activities was reached aC50) were 0.12 mgtmL for the CH50 test, 0.10 mgtmL for the AP50 test, and 0.12 mgtmL for the LP50 test (Fig. 1) .
DXS Dose-Dependently Inhibits Deposition of Human Complement on Pig Cells and Cytotoxicity: Inhibition
Correlates with Binding of DXS to the Cells Pig cells (PAEC and PK15) were incubated with fresh NHS, and complement deposition was analyzed by FACS. Preincubation of the cells with different concentrations of DXS, followed by washing, resulted in a do~e-dependent inhibition of C3c deposition ( Fig. 2A ) with an IC50 of 1.2 mgtmL. Similar results were obtained for the deposition of C1q aC50=1.4 mgtmL) and C4c aC50=1.1 mgtmL). Parallel to complement deposition, the cytotoxicity of human serum against the porcine cells was dose-dependently reduced from 52%:!:0.8% lysis without DXS to 18%:!:0.5% lysis with 25 mgtmL, as assessed by propidium iodide staining. No changes were observed for deposition of human IgM and IgG (data not shown). That complement inhibition correlated with an increased binding of DXS to the cells was shown by using DXS-Fluo, which bound dose-dependently to PK15 r FIGURE 1. Dextran sulfate (DXS) inhibits all three pathways of complement activation. Hemolytic assays for the classic (CH50), alternative (AP50), and lectin (LP50) complement pathways were performed to evaluate the efficacy and specificity of complement inhibition. DXS (.) dose-dependently inhibited hemolysis in all tests (A: CH50, B: AP50, C: LP50) with an approximate IC50 of 0.1 mg/mL. Lysis by normal human serum (NIlS) without addition of DXS (horizontal lines at 100%). Average values of at least three experiments with indication of the standard deviations. cells and PAECs ( Fig. 2A) . A significant correlation (r=0.95, P<0.005 by analysis of variance) was found between the mean fluorescence (MF) values for C3c deposition and the log (MF) values for binding of DXS-Fluo (Fig. 2B) . As determined by live and dead staining (Molecular Prooes Europe, Leiden, The Netherlands), incubation of porcine cells with DXS up to a concentration of 100 mg/mL for 24 hr demonstrated no toxic effects on PAECs or PK15 in vitro.
Time Course of DXS-Mediated Endothelial Cell Protection
In Vitro
To evaluate the efficacy of DXS-mediated EC protection over time, PAECs were preincubated with DXS (0.04-25 mg/mL) for 30 min and then washed. Culturing of the cells was continued under normal conditions for 0 to 48 hr. and protection from complement activation on the cell surface was then tested by incubation of the cells with NHS. DXSpretreated PAECs were dose-dependently protected from C3c deposition with IC50 values of 0.7 mg/mL at 0 hr, 0.9 mg/mL at 4 hr, 1.7 mg/mL at 24 hr, and 18 mg/mL at 48 hr after the 30-min DXS incubation (Fig. 3) . These results show that DXS is still efficient in protecting pig cells from deposition of human complement for up to 48 hr after treatment.
Increased Binding of DXS-Fluv to Porcine Aortic Endothelial Cells Pre incubated with Normal Human Serum or Heparinase-I
To see whether binding of DXS to the EC surface is favored by release of HSPG from the cell surface, PAECs were incubated with human serum or heparinase as controls. Incubation with NHS led to a 44% decrease of FACS staining for HSPG, and after heparinase treatment, a reduction of 37% was observed (Fig. 4) . Untreated PAECs and PAECs treated with NHS or heparinase were then incubated with DXS-Fluo from 0.04 to 5 mg/mL. Compared with untreated PAECs (percentage of F ACS-positive cells at 5 mg DXS-Fluo/mL set to 100%), the binding of DXS-Fluo was dose-dependently increased in PAECs incubated with NHS (220% at 5 mg DXS-Fluo/mL) or heparinase (142%) (Fig. 4) DXS Inhibits Natural Killer Cell-Mediated Xenogeneic Cytotoxicity To assess the capacity of DXS to protect porcine ECs from not only complement-mediated cytotoxicity but also NK cellmediated cytotoxicity, we tested NK92-mediated lysis of PED in standard 51Cr release assays (Fig. 5) . The mean lysis of PED cells at the highest E:T ratio of 40: 1 was 52.7% in four independent experiments (range 45.2%-61.0%) at the lowest E:T ratio of 5:1, the mean lysis still reached 34.4% (25.3%-45.9%). TNF-a stimulation ofPED enhanced NK92-mediated lysis to 69.3% (60.6%-79.9%) at a 40:1 ratio and 57.3% (45.5%-75.6%) at a 5:1 ratio. NK cytotoxicity was significantly reduced after treatment of PED with 25 mg/mL DXS for 30 min before coincubation with NK92 effector cells (Fig.  5A ). This protective effect of DXS was enhanced when PED cells were activated by serum deprivation (data not shown) or by TNF-a stimulation (Fig. 5B ) before coincubation with NK92 cells. The protective effect of DXS was specific for ECs because NK92-mediated lysis of K562 )Vas not reduced (Fig.  5C ). When the mean percentage of inhibition by DXS was calculated from all four E:T ratios of four independent experiments, DXS treatment led to a 25.3% inhibition (P<0.0001) of NK92-mediated lysis, whereas the mean percentage of inhibition by DXS on NK92-mediated lysis of TNF -a-stimulated PED cells was 47.3% (P=0.0002).
DISCUSSION
It has been known for at least a decade that low MW DXS is an efficient inhibitor of complement activation (15, 16, 24) . (17) . We therefore tested whether DXS mainly acts as a fluid-phase complement inhibitor or whether it can also bind to the EC surface and provide direct protection to the endothelium. In the present study, we showed that DXS inhibited all three pathways of complement activation and dose-dependently protected pig cells from deposition of human complement, and that the EC-protective effect of DXS correlated with binding of the substance to the cells. In addition, we showed that binding of DXS to porcine cells increased after treatment of the cells with NHS or heparinase. The latter finding indicates that the release of HSPG from the EC surface, as it is known to occur after activation ofECs (e.g., by XNAs and complement) <13), favors the binding of DXS. We therefore hypothesize that DXS might at least functionally replace the shed HSPG on the EC surface and thereby act as a "repair coat," preventing further damage of the cells by reestablishing an anticoagulant and antiinflammatory surface (Fig. 6) .
In the xenotransplantation setting, EC activation is a crucial step in the pathophysiology of A VR, and recent data indicate that the classic complement pathway plays a major role in human serum-induced activation of porcine ECs (25) . Because transgenic (over)expression of human complement regulatory proteins on the surface of porcine ECs is able to prevent HAR (b~t does not prevent subsequent AVR), there is still no efficient treatment available to date. The properties of DXS described in this article, namely, the blocking of all three pathways of complement activation and the preferential binding to activated ECs that have lost their protective layer of HSPG, indicate that DXS might be of use for the treatment of A VR. Therefore DXS may fill a gap in our current armamentarium to fight xenorejection. However, it remains to be determined by in vivo experiments whether the known side effects of DXS, mainly its anticoagulant properties, will preclude a clinical application. With the concept of reestablishing an anticoagulant and anti-inflammatory surface (or "glycolandscape") of the EC, after activation-induced release of HSPG, we consider DXS a prototype of an EC protectant. This view is supported by reports from other .. showing that DXS is able to protect cells from free radical injury (26) .
NK cells are part of the innate immune system and as such are involved in the early recognition and rejection of xenografts (11) . We have shown that expression of human MHC class I molecules on porcine EC reduces xenogeneic NK cellmediated cytotoxicity (27) . However, because this protection was only partial, additional strategies are needed to protect xenografts from NK cell-mediated damage. Indeed, as demonstrated in the present study, DXS partially inhibited the lysis of porcine EC by human NK cells. It was shown earlier that the mouse NK cell receptor Ly49 (corresponding to the human NKG2 family) binds to MHC class I molecules and acts as adhesion receptor. This interaction was inhibited by sulfated dextran MW 500'000 (50% inhibition at 10-9 M) and fucoidan, whereas several other polysaccharides of similar size and negative charge showed no effect (28) . DXS may thus mask endothelialligands for NK activation receptors, as supported by our findings that the protective effect of DXS is enhanced on activated endothelium, and that NK cell-mediated lysis of stimulated EC is reduced to the level of resting EC. Notably, this effect was specific for ECs because lysis of the standard NK target cell line K562 was not affected by DXS.
We reported studies using in vitro models. It will be important to examine the capacity of DXS to act as an EC protectant in vivo. Our preliminary results in different experimental models are consistent with this likelihood.
